METTL14 and diabetic kidney disease: On one hand, METTL14 has been shown to regulate m6A and modify TUG1, thereby activating the MAPK/ERK signaling pathway, which promotes the death of renal tubular epithelial cells and exacerbates ERS, accelerating the progression of DKD (Zheng et al., 2023).